医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

腫瘍学

沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台，树立高分辨质谱性能新标杆

沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台，树立高分辨质谱性能新标杆

バイオテクノロジーヘルスケア医療機器腫瘍学　 TimeLine: 分辨质谱性能新标杆沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台

2021年06月15日

Kheiron’s AI Breast Screening Solution Mia® Receives Regulatory Clearance in Australia and New Zealand

その他ヘルスバイオテクノロジーヘルスケア放射線学腫瘍学　 TimeLine: Breast Screening Solution Mia Kheiron’s AI Receives Regulatory Clearance in Australia and New Zealand

2021年06月15日

HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncology Programs and Validate Its DIS™ Approach in the Clinic

その他ヘルスバイオテクノロジーヘルスケアヘルス一般感染症腫瘍学臨床試験製薬　 TimeLine: $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncology Programs and Validate Its DIS Approach in the Clinic HiFiBiO Therapeutics Closes

2021年06月14日

Telix Pharmaceuticals and Applied Radiology Launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research

Telix Pharmaceuticals and Applied Radiology Launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research

その他ヘルスバイオテクノロジーヘルスケア外科放射線学腫瘍学製薬遺伝学　 TimeLine: Telix Pharmaceuticals and Applied Radiology Launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research

2021年06月14日

アジェンディアのマンマプリント検査、NSABP B-42試験で長期内分泌療法の利点を予測する能力を初めて示す

アジェンディアのマンマプリント検査、NSABP B-42試験で長期内分泌療法の利点を予測する能力を初めて示す

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: NSABP アジェンディアマンマプリント検査利点長期内分泌療法

2021年06月14日

Celltrion Healthcare presents the first real-world data for Truxima® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress

Celltrion Healthcare presents the first real-world data for Truxima® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: B-cell lymphoma at the Biosimilar Rituximab Celltrion Healthcare presents the first real-world data for Truxima EHA 2021 Virtual Congress in patients with diffuse large

2021年06月13日

Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma and Adult T-Cell Leukemia/Lymphoma

Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma and Adult T-Cell Leukemia/Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: Lymphoma Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma and Adult T-Cell Leukemia

2021年06月11日

Telix Launches “Gallium Wave” Awareness Website

Telix Launches “Gallium Wave” Awareness Website

バイオテクノロジーヘルスケアヘルス一般放射線学腫瘍学臨床試験製薬　 TimeLine: Awareness Website Gallium Wave Telix Launches

2021年06月11日

BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021

BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021

ヘルスケア腫瘍学製薬　 TimeLine: and Tislelizumab at EHA BeiGene Presents Long-Term Efficacy and Safety Results Three Pivotal Trials of BRUKINSA zanubrutinib

2021年06月11日

BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia

BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia

その他ヘルスバイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia zanubrutinib

2021年06月11日